Compare VanEck Gold Miners ETF (GDX) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Gold Miners ETF vs Novo Nordisk A/S — how do they compare? VanEck Gold Miners ETF trades at $71.4, while Novo Nordisk A/S trades at $50.65 (market cap $222.24B). The key difference: Novo Nordisk A/S pays a 3.56% dividend while VanEck Gold Miners ETF pays none, and Novo Nordisk A/S is trading nearer its 52-week high, VanEck Gold Miners ETF nearer its low. Which is the better fit depends on your goals.
| GDX | NVO | |
|---|---|---|
52-Week High | $115.84 | $71.70 |
52-Week Low | $51.15 | $35.29 |
Market Cap | — | $222.24B |
Sector | — | Health |
Enterprise Value | — | $241.20B |
Dividend Yield | — | 3.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GDX (VanEck Gold Miners ETF) trades at $71.42, down 4.62% with bearish technical signals from moving averages. The fund faces competition from lower-fee gold ETFs while offering mining equity exposure with higher volatility. Recent portfolio changes include the addition of Aya Gold & Silver, potentially enhancing diversification. Technical indicators show neutral oscillators but overall bearish momentum with key support at $70.
The outlook remains cautious as gold miners navigate gold price volatility and fee competition. Upside potential exists if gold rebounds, but investors face risks from sector underperformance relative to physical gold. Analyst views are mixed, with some seeing value in discounted valuations while others highlight structural challenges in the mining ETF space.
Novo Nordisk (NVO) trades at $51.52, up 4.99% in the last session, with strong technical momentum and bullish moving averages. The company maintains robust fundamentals, including a 37.2% net income margin and consistent earnings beats in recent quarters. Recent EU approval for the Wegovy weight-loss pill (Reuters, 2026-07-15) reinforces its leadership in GLP-1 therapies, though competition is intensifying.
Outlook remains positive given solid cash flow growth and analyst support, but risks include pricing pressure from generics and slowing prescription trends. The stock's valuation at a P/E of 12.14 offers relative value in the pharma sector, with upside potential if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Gold Miners ETF
The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
